Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OSI Developing Tarceva I.V. Formulation, Expected To Aid In Reimbursement

Executive Summary

OSI Pharmaceuticals is developing an intravenous formulation of its investigational anticancer agent Tarceva, which should facilitate reimbursement for the investigational anticancer agent
Advertisement

Related Content

Roche Will Challenge Amgen In U.S. EPO Market; Oncology Business Growing
Roche Will Challenge Amgen In U.S. EPO Market; Oncology Business Growing
Erbitux BLA Resubmission Plan Set; Will Test Accelerated Approval Rules
OSI Confident On Tarceva After Iressa Approval; Brain Cancer Is Back-Up Plan
Iressa Approval Upholds Standard For Oncology Subpart H Approvals – FDA
Iressa Activity Not Likely Predicted By EGFR Expression Level – AstraZeneca
Iressa Patients’ Lack Of Rash Suggests Dose Is Too Low For Benefit – OSI
Oral Cancer Drug Coverage Bill May Move In Combo With AWP Reform
Oral Cancer Drug Coverage Bill May Move In Combo With AWP Reform
Advertisement
UsernamePublicRestriction

Register

PS041973

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel